The Enteral Feeding Formula Market is to Touch $6.07 Billion by 2030; Increasing Cancer Prevalence and The increasing prevalence of chronic illnesses are fueling the propels market growth.

The Enteral Feeding Formula Market size is estimated to reach $6.07 billion by 2030, growing at a CAGR of 6.5% during the forecast period 2023-2030, according to a recent report published by IndustryARC, titled, “Enteral Feeding Formula Market – By Product Type (Standard Formula (Calorie Dense Products - 1.0 calorie/mL, Calorie Dense Products - 1.2 calorie/mL, Calorie Dense Products - 1.5 calorie/mL, Calorie Dense Products - 2.0 calorie/mL), Specialty Formula (Renal Formulas, Liver Formulas, Diabetes Formulas, Pulmonary Formulas, Immuno Modulatory Formulas, Gastrointestinal Dysfunction Formulas, Others), Blenderized Formula (Fruits, Vegetables, Meat, Seeds and Grains, Dairy, Others), Elemental Formula, Semi-Elemental Formula, Polymeric Formula, Hydrolyzed Formula, Fiber Supplemented Formula, and others.), By Age Category (Adult, and Children), By Form(Powder, and Liquid),  By Flavor(Flavored (Vanilla, Strawberry, Butter Pecan, and Others), and Unflavored), By Mode of Delivery(Oral, Gastric (Nasogastric, Oro-Gastric, Gastrostomy), Tans-pyloric (Naso-jejunal, Gastro-jejunostomy, Jejunostomy)), By Application (Oncology, Gastroenterology, Neurology, Diabetes, Critical Care, and Others), By End-Use Industry (Hospitals & Clinics, Nursing Homes, Home Care & Hospice Agencies, Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2023-2030” ; Increasing Cancer Prevalence and The increasing prevalence of chronic illnesses are fueling the growth of the Enteral Feeding Formula industry during the forecast period.

Based on geographic distribution, the North American Enteral Feeding Formula Market accounted for 35% of revenue share in 2023. This is primarily due to the increasing prevalence of chronic diseases such as diabetes, cancer, and neurological conditions. The American Cancer Society reported that in 2023, the United States anticipated 1,958,310 new cancer cases and 609,820 cancer-related deaths, averaging about 5,370 cases per day.

The market for enteral feeding formulas is accelerating due to the rising prevalence of cancer worldwide. The increasing incidence of cancer diseases such as lung, breast, liver, and stomach cancer has led to higher mortality rates. According to the World Health Organization, in 2022, there were 20 million new cancer cases and 9.7 million deaths globally. Approximately 53.5 million individuals survived five years post-diagnosis. On a global scale, about 1 in 5 people develop cancer in their lifetime, with mortality rates of 1 in 9 for men and 1 in 12 for women. Cancer cachexia, a condition affecting the majority of cancer patients, results in insulin resistance, accelerated lipolysis with body fat loss, increased protein turnover, muscle mass loss, and a decrease in appetite and weight. The prevalence of cancer varies by region, with Asia accounting for more than half of all cancer cases and Europe for one-quarter. Given the difficulty cancer patients often face in eating food orally, nutrition becomes crucial for improving their clinical condition. As treatment progresses, enteral feeding tubes are used to provide nutrition, helping patients maintain their body mass. This necessity drives the demand for enteral feeding formulas and boosts market growth.

A major driver in the enteral feeding formula market is the ageing population and the increasing prevalence of chronic diseases globally. As populations age, there is a higher incidence of chronic conditions that impair normal eating and digestion, necessitating enteral feeding as a vital source of nutrition. Diseases such as stroke, dementia, and Parkinson's disease often result in dysphagia or difficulty swallowing, making enteral feeding a crucial intervention to ensure adequate nutrient intake and maintain overall health. Additionally, conditions like cancer and gastrointestinal disorders require specialized enteral formulas tailored to meet specific nutritional needs and support recovery. The ageing population's susceptibility to malnutrition and its associated complications further underscores the importance of enteral feeding formulas in managing nutritional deficiencies and promoting healing. Healthcare providers are increasingly recognizing the benefits of enteral nutrition in improving patient outcomes and quality of life, driving the demand for advanced enteral feeding solutions.

• In May 2023, Otsuka Pharmaceutical Factory introduced a new variant of ENORASⓇ Liquid for Enteral Use, offering an additional 200 kcal/125 mL with delightful coffee and tea flavors. Ideal for feeding tubes and oral administration.

• Feb 2023, Nestlé Health Science and EraCal Therapeutics have joined forces in a research collaboration to discover innovative nutraceuticals for regulating food intake. The Swiss-based partnership seeks to advance the development of solutions in this crucial aspect of health and nutrition.

• In September 2022, Kate Farms™ launched Adult Standard 1.4, a high-calorie medical formula in chocolate flavor, advancing plant-based nutrition in healthcare. Offering organic ingredients, it caters to diverse dietary needs, aiming for nourishment and taste.

Key companies profiled in the Enteral Feeding Formula Market Abbott Laboratories, Nestle SA, Fresenius Kabi AG, B. Braun Melsungen AG, Nutricia, Medtrition, Inc., EN Otsuka Pharmaceutical Co., Ltd., WHOLE Enteral Nourishment, Vonco Products, LLC., Meiji Holdings Co., Ltd. and others.